Serum Levels of Inflammatory Proteins Are Associated With Peripheral Neuropathy in a Cross-Sectional Type-1 Diabetes Cohort.
Serum Levels of Inflammatory Proteins Are Associated With Peripheral Neuropathy in a Cross-Sectional Type-1 Diabetes Cohort.
复制标题
炎性蛋白的血清水平与横截面1型糖尿病队列中的周围神经病有关。
DOI:
10.3389/fimmu.2021.654233
复制
发表时间:
2021
影响因子:
7.3
通讯作者:
She JX
中科院分区:
文献类型:
--
作者:
Purohit S;Tran PMH;Tran LKH;Satter KB;He M;Zhi W;Bai S;Hopkins D;Gardiner M;Wakade C;Bryant J;Bernard R;Morgan J;Bode B;Reed JC;She JX
Chronic low-grade inflammation is involved in the pathogenesis of type-1 diabetes (T1D) and its complications. In this cross-section study design, we investigated association between serum levels of soluble cytokine receptors with presence of peripheral neuropathy in 694 type-1 diabetes patients. Sex, age, blood pressure, smoking, alcohol intake, HbA1c and lipid profile, presence of DPN (peripheral and autonomic), retinopathy and nephropathy was obtained from patient’s chart. Measurement of soluble cytokine receptors, markers of systemic and vascular inflammation was done using multiplex immunoassays. Serum levels were elevated in in DPN patients, independent of gender, age and duration of diabetes. Crude odds ratios were significantly associated with presence of DPN for 15/22 proteins. The Odds ratio (OR) remained unchanged for sTNFRI (1.72, p=0.00001), sTNFRII (1.45, p=0.0027), sIL2Rα (1.40, p=0.0023), IGFBP6 (1.51, p=0.0032) and CRP (1.47, p=0.0046) after adjusting for confounding variables, HbA1C, hypertension and dyslipidemia. Further we showed risk of DPN is associated with increase in serum levels of sTNFRI (OR=11.2, p<10), sIL2Rα (8.69, p<10-15), sNTFRII (4.8, p<10-8) and MMP2 (4.5, p<10-5). We combined the serum concentration using ridge regression, into a composite score, which can stratify the DPN patients into low, medium and high-risk groups. Our results here show activation of inflammatory pathway in DPN patients, and could be a potential clinical tool to identify T1D patients for therapeutic intervention of anti-inflammatory therapies.
登录
查看更多内容
影响因子:
5.2
作者:
Burrack AL;Martinov T;Fife BT
通讯作者:
Fife BT
影响因子:
16.2
作者:
Jaiswal M;Divers J;Dabelea D;Isom S;Bell RA;Martin CL;Pettitt DJ;Saydah S;Pihoker C;Standiford DA;Dolan LM;Marcovina S;Linder B;Liese AD;Pop-Busui R;Feldman EL
通讯作者:
Feldman EL
DOI:
10.1155/edr.2003.65
发表时间:
2003-04
期刊:
Experimental diabesity research
影响因子:
--
作者:
Satoh J;Yagihashi S;Toyota T
通讯作者:
Toyota T
DOI:
10.1016/j.ecl.2010.05.009
发表时间:
2010-09-01
影响因子:
4.5
作者:
Melendez-Ramirez, L. Yvonne;Richards, Robert J.;Cefalu, William T.
通讯作者:
Cefalu, William T.
影响因子:
16.2
作者:
Herman, WH;Kennedy, L
通讯作者:
Kennedy, L